

Copies to: [REDACTED]

E. I. du Pont de Nemours and Company
Haskell Laboratory for Toxicology and Industrial Medicine
HASKELL LABORATORY REPORT NO. 244-71 [REDACTED]

Material Tested: [REDACTED]

Material Submitted by: [REDACTED]

Haskell No.: 6917

Organic Chemicals Department
Jackson Laboratory

Other Codes: [REDACTED]

ACUTE ORAL TEST

Procedure: The test material, as an aqueous suspension, was administered by intragastric intubation to young adult ChR-CD male rats in single doses. Survivors were sacrificed 14 days later; the livers were removed for gravimetric analysis.

Results:

Suspension (%)	Dose (mg/kg)	Mortality*	Weight When Killed (g)		L.W./B.W. X 100	Clinical Signs	ALD
			Body	Liver			
25	11,000†	S - 14 d.	301	12.68	4.2	None	> 11,000 mg/kg
25	7,500†	S - 14 d.	319	14.15	4.4		
25	5,000	S - 14 d.	352	15.65	4.4		
25	3,400	S - 14 d.	328	14.55	4.4		
25	2,250	S - 14 d.	312	13.79	4.4		

* S - () d. = Sacrificed () days after dosing

† Administered in divided dose

TEN-DOSE ORAL SUBACUTE TEST

Procedure: The test material was administered by intragastric intubation, as a 15% aqueous suspension, to a group of six young adult ChR-CD male rats, five times a week for two weeks; an additional group of six rats served as controls and was intubated with distilled water. Three control and three test rats from each group were sacrificed approximately four hours and 14 days after the last dose.

Results:

Dose (mg/kg/day)	Mortality	Weight of Liver (g)		L.W./B.W. X 100		Gross Pathology† on Liver		Histopathology† on Liver	
		Animals Killed:		Animals Killed:		Animals Killed:		Animals Killed:	
		After 10th Dose	14 Days After 10th Dose	After 10th Dose	14 Days After 10th Dose	After 10th Dose	14 Days After 10th Dose	After 10th Dose	14 Days After 10th Dose
2250	0/6	23.0	17.8	7.8	5.6	1	-	B	B
		27.0	18.6	8.2	4.8	1	-	A+,B	B
		21.9	16.8	7.9	4.9	1	-	B	B
0 (Control)	0/6	13.0	17.1	4.2	4.3	-	-	-	B
		13.9	13.3	4.2	4.0	-	-	-	-
		8.4	18.1	3.6	4.1	-	-	B,C	-

In addition, the following organs were examined histologically: brain, eyes, stomach, duodenum, thymus, spleen, bone marrow, pancreas, adrenal, kidney, testis, epididymis, lung and trachea; no compound-related histologic changes were observed in any of these organs.

No clinical signs were observed during the first week of the test phase. During the second week and the recovery period, the test animals gained weight at a rate slightly less than that of the controls.

† Gross and histopathologic code:

- = No abnormality detected
- 1 = Large and heavy
- A = Degeneration and necrosis of isolated hepatocytes
- B = Reduction in number of centrilobular cytoplasmic vesicles
- C = Focal RE cell hyperplasia
- + = Slight degree of change

Summary: [REDACTED] has low acute toxicity when administered orally to young adult ChR-CD male rats; its Approximate Lethal Dose (ALD) is greater than 11,000 mg/kg of body weight. There was neither gross nor gravimetric evidence of liver enlargement 14 days after dosing.

The repeated administration of the test compound to rats at 2250 mg/kg/day for ten doses produced heavier liver weights and larger liver/body weight ratios at the end of the test phase. These values returned to the normal range after the 14-day recovery period. The histologic effect which was present at the end of the test period and after the 14-day recovery period was characterized by a depletion of cytoplasmic vesicles, which are usually found in centrilobular hepatocytes of control male rats of this age group. Recovery from this type of liver change probably would have occurred if the recovery period had been longer.

Report by:

Kathleen S. Carroll

Kathleen S. Carroll
Oral Toxicology Section

Approved by:

John A. Zapp, Jr.

John A. Zapp, Jr.
Director

[REDACTED]
KSC:pgh

Date: July 20, 1971